Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$91.95 USD

91.95
543,720

+0.45 (0.49%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $92.05 +0.10 (0.11%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod

by Zacks Equity Research

Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.

Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout

by Zacks Equity Research

Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.

Derek Lewis headshot

3 Stocks to Buy for Consistent Sales Growth

by Derek Lewis

Consistency is key, particularly whenever it concerns generating sales. For those seeking top line compounders, these three companies fit the criteria nicely.

Insulet (PODD) Gains From Product Innovation, Global Expansion

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down

by Zacks Equity Research

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.

Align Technology (ALGN) Q4 Revenues Top, Margins Expand

by Zacks Equity Research

Align Technology (ALGN) surpasses revenue and earnings estimates in the fourth quarter of fiscal 2023.

Is Haemonetics (HAE) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.

Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls

by Zacks Equity Research

Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.

Thermo Fisher (TMO) End Market Growth Strong Despite Macro Woes

by Zacks Equity Research

Thermo Fisher's (TMO) electron microscopy, chromatography and mass spectrometry businesses are delivering strong growth in the academic and government end market.

QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences

by Zacks Equity Research

QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.

Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise

by Zacks Equity Research

Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.

Align (ALGN) Ailed by Macroeconomic Issues & Currency Headwind

by Zacks Equity Research

Foreign exchange continues to be a major headwind for Align (ALGN) due to a considerable percentage of its revenues coming from outside the United States.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED), backed by the NuVasive merger and its prominence in the musculoskeletal field.

Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm

by Zacks Equity Research

Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched later this year.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.

Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study

by Zacks Equity Research

Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.

Penumbra (PEN) Rides on Vascular Arm Strength Amid FX Woes

by Zacks Equity Research

Penumbra's (PEN) Vascular business is demonstrating strong growth, banking on a rapid increase in sales of vascular thrombectomy products in the United States.

Why Haemonetics (HAE) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.

Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay

by Zacks Equity Research

Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) due to its series of new product launches and promising growth strategy.